Patent intelligence · US
US 12090183
Methods of treating solid or lymphatic tumors by combination therapy
Methods of treating solid or lymphatic tumors by combination therapy
Patent details — US 12090183
- Jurisdiction
- US
- Status
- granted
- Grant date
- Sep 17, 2024
- Expiration
- Sep 12, 2044
- Applicant
- CG ONCOLOGY, INC.
- Claims
- 21
- CPC classes
- A61K, A61K35/761, A61K39/3955, A61P
Quick answer
US 12090183 (Methods of treating solid or lymphatic tumors by combination therapy) is held by CG ONCOLOGY, INC.. Status: granted. Granted Sep 17, 2024. Expires Sep 12, 2044 (18 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- CG ONCOLOGY, INC.
- Grant date
- Expiration
- Claims
- 21
- CPC classes
- A61K, A61K35/761, A61K39/3955, A61P, A61P35/02
More from CG ONCOLOGY, INC.
Related pharmaceutical patents in our USPTO index.
-
US 12370229
Methods of treating bladder cancer
granted -
US 11596660
Methods of treating bladder cancer
granted -
US 11497781
Methods of treating bladder cancer by combination therapy comprising the oncolytic adenovirus CG0070 and an immune checkpoint inhibitor
granted -
US 11338003
Methods of treating bladder cancer with an oncolytic virus
granted
Frequently asked questions
What is US patent 12090183?
US 12090183 (Methods of treating solid or lymphatic tumors by combination therapy) is held by CG ONCOLOGY, INC.. Status: granted. Granted Sep 17, 2024. Expires Sep 12, 2044 (18 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 12090183?
CG ONCOLOGY, INC. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 5 pharmaceutical patents for this assignee.
When does US 12090183 expire?
Our index shows an expiration date of Sep 12, 2044 (18 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.